S

Shenzhen Hepalink Pharmaceutical Group Co Ltd
SZSE:002399

Watchlist Manager
Shenzhen Hepalink Pharmaceutical Group Co Ltd
SZSE:002399
Watchlist
Price: 10.8 CNY -5.1% Market Closed
Market Cap: 13.5B CNY
Have any thoughts about
Shenzhen Hepalink Pharmaceutical Group Co Ltd?
Write Note

Shenzhen Hepalink Pharmaceutical Group Co Ltd
Cash from Investing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Shenzhen Hepalink Pharmaceutical Group Co Ltd
Cash from Investing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Investing Activities CAGR 3Y CAGR 5Y CAGR 10Y
S
Shenzhen Hepalink Pharmaceutical Group Co Ltd
SZSE:002399
Cash from Investing Activities
-ÂĄ317m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
18%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Cash from Investing Activities
ÂĄ1.1B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Cash from Investing Activities
ÂĄ7B
CAGR 3-Years
N/A
CAGR 5-Years
66%
CAGR 10-Years
N/A
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Cash from Investing Activities
-ÂĄ1.9B
CAGR 3-Years
N/A
CAGR 5-Years
9%
CAGR 10-Years
-25%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Cash from Investing Activities
ÂĄ5.9m
CAGR 3-Years
-88%
CAGR 5-Years
-80%
CAGR 10-Years
N/A
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Cash from Investing Activities
-ÂĄ81.9m
CAGR 3-Years
27%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Shenzhen Hepalink Pharmaceutical Group Co Ltd
Glance View

Market Cap
13.5B CNY
Industry
Pharmaceuticals

Shenzhen Hepalink Pharmaceutical Group Co Ltd is a CN-based company operating in Pharmaceuticals industry. The company is headquartered in Shenzhen, Guangdong and currently employs 2,046 full-time employees. The company went IPO on 2010-05-06. Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based pharmaceutical company focused on the field of heparin sodium preparations and raw materials, macromolecular drugs contract development manufacturing organization (CDMO) and innovative drug development. The Company’s main products and services include enoxaparin sodium preparations and heparin sodium bulk medicines, enoxaparin sodium bulk medicines, and CDMO services for macromolecular drugs. The firm distributes its products within the domestic market and to overseas markets, including Turkey, Brazil, the United States and others.

Intrinsic Value
12.99 CNY
Undervaluation 17%
Intrinsic Value
Price
S

See Also

What is Shenzhen Hepalink Pharmaceutical Group Co Ltd's Cash from Investing Activities?
Cash from Investing Activities
-317m CNY

Based on the financial report for Sep 30, 2024, Shenzhen Hepalink Pharmaceutical Group Co Ltd's Cash from Investing Activities amounts to -317m CNY.

What is Shenzhen Hepalink Pharmaceutical Group Co Ltd's Cash from Investing Activities growth rate?
Cash from Investing Activities CAGR 10Y
18%

Back to Top